Form 4: Y-mAbs Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, exercised stock options to acquire 22,831 shares of common stock.
Summary
- On September 19, 2024, Thomas Gad, the Chief Business Officer of Y-mAbs Therapeutics, exercised employee stock options.
- This transaction resulted in the acquisition of 22,831 shares of common stock at a price of $4.38 per share.
- Following the transaction, Gad directly owns 181,531 shares.
- Gad also indirectly owns 67,681 shares through GAD Enterprises LLC and 60,000 shares through his children.
- The exercised employee stock options were fully vested and exercisable.
Sentiment
Score: 6
Explanation: The document is a neutral regulatory filing. The exercise of options could be seen as a slightly positive sign, but it's a routine event.
Positives
- The exercise of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 09/19/2024 | Date of the stock option exercise and acquisition of shares. |
| 09/20/2024 | Date of signature of the Form 4 filing. |
| 10/21/2026 | Expiration date of the employee stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.